Skip directly to content

Objectives for Module 4:

  1. Review a brief history of HIV/AIDS policy advocacy
  2. Understand basic tactics for policy advocacy and how it differs from other kinds of advocacy
  3. Go over suggestions for developing an advocacy agenda and action plan
  4. Discuss some of the primary options in our “advocacy toolbox”

The goal of policy advocacy is to change official policies, laws, and practices.

Objectives for Module 3:

  1. Discuss examples of “structural determinants” and “social determinants” of health that drive the HIV epidemic
  2. Discuss the difference between individual, structural, and social interventions
  3. Look at examples of structural and social interventions for HIV prevention

Current HIV prevention science may theoretically have the potential to end epidemics, but even our most promising prevention tools cannot overcome laws, policies, and structural barriers that limit access to healthcare and perpetuate epidemics within our most marginalized communities.

Objectives for Module 2:

  1. Discuss what HEALTH INDICATORS are, what they are not, and why they are important
  2. Look at some of the current indicators and relevant research to see how well we’re doing with HIV prevention in key populations in the United States
  3. Identify current opportunities for advocacy to improve our current HIV prevention indicators

How well are we doing with our HIV prevention efforts?

Determining the answer to this question can be difficult, subjective, and inconsistent across communities.

Objectives for Module 1:

  1. Discuss the difference between HIV prevention for HIV-negative people, HIV prevention for people living with HIV, and HIV testing
  2. Discuss the evidence-based HIV prevention options we have available
  3. Overview of new tools in development

In many ways, we are in an HIV-prevention renaissance.

Since the early days of the HIV/AIDS epidemic, community-led advocacy has been an essential component of local, national, and international responses to the crisis. Without the direct involvement of those most affected by the virus, we may never have seen a robust response to this deadly and highly stigmatized disease. In the United States, it is because of community advocacy that the government stopped neglecting affected communities and dramatically scaled up funding to develop and provide effective care and treatment for people living with HIV/AIDS.

In recent years, growing numbers of

Treatment Action Group, Health GAP, AIDS-Free World, and Treatment Action Campaign Urge G20 Leaders to Fund Research to End TB
NEW YORK CITY, NY; UNIONDALE, NY; JOHANESSBURG, SOUTH AFRICA;March 23, 2017—In advance of World TB Day, Treatment Action Group (TAG), Health GAP, AIDS-Free World and Treatment Action Campaign (TAC) urge G20 member states to commit by the July 7, 2017 G20 summit to increase annual funding contributions to USD $1.17 billion for research and development (R&D) to set us on the path to end tuberculosis (TB).


No Time to Lose: G20 Leadership in TB Research Needed to End TB

March 2017--Tuberculosis (TB) is the leading infectious cause of death, and drug-resistant forms of TB account for one in three deaths from antimicrobial resistance. TB research has received scant resources, limiting the possibility of developing the new diagnostic, treatment, and prevention options urgently needed to end TB. In this brief, TAG challenges G20 member states to collectively spend $5.8 billion on TB research and development between 2016 and 2020.

NEW YORK, NY, March 20, 2017 – Treatment Action Group (TAG) releases this statement in strong opposition to the President’s 2018 budget blueprint. The blueprint threatens research essential to ending the epidemics of HIV/AIDS, tuberculosis (TB), and hepatitis C virus (HCV) in the United States and globally by cutting funding and eliminating programs.

Treatment Action Group (TAG) is interested in learning more about your perspectives on the provision of Truvada for pre-exposure prophylaxis (PrEP) in clinical trials of biomedical prevention interventions (e.g. HIV vaccines, antibody or immune-based prevention interventions, and other forms of antiviral PrEP).

Guidelines[1] recommend that the state of the art package of prevention services (risk reduction counseling, condoms and lube, circumcision, and/or PrEP) known as the "standard of prevention" be provided to all HIV prevention clinical trial participants.